Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.